Medicortex Finland Oyj

Medicortex was granted a Finnish patent related to the detection of tissue damage


Medicortex Finland Plc, a biopharmaceutical company focusing on the development of diagnostics and drug for mild traumatic brain injury (TBI), was granted a Finnish patent for detection of tissue damage and orthopaedic injuries otherwise needing X-ray/CT/MRI. This patent protects Medicortex’s unique detection method for such tissue damages based on the presence of a specific glycan in urine.

Medicortex’s tissue damage diagnostics patent “Method of detecting tissue damage” was granted in Finland (FI patent No. 130428). The patent covers testing of carbohydrates specific to tissue damage in urine of patients for detection of orthopaedic injury. This is a unique approach since the current detection methods are using radiation and they require arriving to a medical facility, trained personnel, and depend on equipment availability, all at high cost. The diagnostic kit to be developed by Medicortex will enable self-testing in order to determine the need to go to a hospital to be further analysed.

Medicortex has once again received confirmation of its strength in patent protecting the innovations and new technologies it has developed in-house by its experienced research team.

Dr. Harel, CEO of Medicortex says: “The diagnostic kit Medicortex is developing will enable a person to test him/herself using a non-invasive body fluid sample such as urine or saliva in order to determine if an actual tissue damage has occurred and if so, he/she will definitely need to go to a hospital for further analysis. This kit can help reduce dramatically the cost and time needed for diagnosis of such injuries.”

The company has applied for a research grant to further advance the R&D project related to this invention.

Medicortex has currently a funding round ending on 31st of August with beneficial terms of one free option for each share purchased. More information about the current share issue is available at:

Forward-looking statements

Certain statements in this communication are forward-looking statements. They are based on the views of the company’s management, as well as the understanding and assumptions of the company’s management based on the information available at present, and due to this, they may be forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors, which may result in that the company’s actual future results, operations, achievements, and performance of the sector may differ significantly from the results, operations, achievements, and performance specifically or indirectly indicated in such forward-looking statements. Such risks, uncertainties and other important factors include, among other things, risks related to the implementation of the company’s strategy and availability of financing, general economic and market situation, and other risks. Forward-looking statements are not a guarantee of the company’s operational or financial performance in the future.



Adrian Harel, CEO
Tel: +358 400 488 817


About the company

Medicortex Finland Oyj (Plc) is a biotechnology company dedicated to improving the diagnostics and treatment of Traumatic Brain Injury (TBI). Its current focus is on developing biomarker diagnostics to detect brain injury easily. The company has technology to capture biomarkers from urine and saliva and capability to develop an affordable diagnostic tool to detect biomarkers. Company's second goal is to develop new compounds to serve as drug candidates to halt progression of brain injury and reduce the secondary degeneration. Medicortex was founded by an Israeli Neurobiologist Adrian Harel (PhD, MBA) and the company is based in Turku, Finland.

Subscribe to releases from Medicortex Finland Oyj

Subscribe to all the latest releases from Medicortex Finland Oyj by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Medicortex Finland Oyj

Turun kaupunki myönsi Medicortexille TKI-setelin15.6.2023 13:21:40 EEST | Tiedote

Medicortex Finland Oyj, turkulainen aivovammojen diagnostiikkaan ja lääkekehitykseen erikoistunut yritys, on saanut 5000 euron arvoisen TKI (tutkimus, kehitys- ja innovaatio-osaaminen) -setelin Turun kaupungilta. Seteli käytetään Turun yliopiston kanssa yhteistyössä tehtävän tutkimushankkeen edistämiseen. Hankkeen tarkoituksena on tutkia sähkömagneettisen säteilyn vaikutusta keskushermostoon koe-eläinmallissa.

Medicortexin kevään 2023 osakeanti päättynyt – yhtiö kiitollinen yleisön mielenkiinnosta30.5.2023 10:45:00 EEST | Tiedote

Medicortex Finland Oyj, tapaturmaisen aivovamman diagnostiikkaa ja hoitoa kehittävä turkulainen bioteknologiayhtiö, on saanut päätökseen osakeantikampanjan toisen kierroksen. Kampanjan aikana, joka sijoittui 2023 vuoden ensimmäiselle puolikkaalle, yritys keräsi yli 110 000 euroa. Saadut varat käytetään uusien hankkeiden aktivoimiseen yhtiön ensisijaisen tuotekehitysprojektin rinnalla.

Medicortex concluding the fundraising round of spring 2023 – company grateful for the public interest30.5.2023 10:45:00 EEST | Press release

Medicortex Finland Plc, a biopharmaceutical company focusing on the development of diagnostics for mild traumatic brain injury (TBI), and drug development for the same indication, announces completion of a second round of the fundraising campaign. In the two funding rounds that took place in the first half of 2023, the company has raised more than 110,000 euros. The funds raised will be used to activate research projects in parallel to company’s main product development program.